Pulmonary Disorders and COVID-19: Difference between revisions
Jump to navigation
Jump to search
Sara Mohsin (talk | contribs) |
Sara Mohsin (talk | contribs) |
||
Line 21: | Line 21: | ||
===Increased mortality in COPD patients=== | ===Increased mortality in COPD patients=== | ||
*According to a study conducted in China, having an underlying comorbidity such as chronic obstructive pulmonary disease (COPD) conferred a mortality hazard ratio of 2.681, even after adjusting for smoking status.<ref name="pmid32217650">{{cite journal| author=Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM | display-authors=etal| title=Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. | journal=Eur Respir J | year= 2020 | volume= 55 | issue= 5 | pages= | pmid=32217650 | doi=10.1183/13993003.00547-2020 | pmc=7098485 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32217650 }} </ref><ref>https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184</ref><ref>https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184</ref> | *According to a study conducted in China, having an underlying comorbidity such as chronic obstructive pulmonary disease (COPD) conferred a mortality hazard ratio of 2.681, even after adjusting for smoking status.<ref name="pmid32217650">{{cite journal| author=Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM | display-authors=etal| title=Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. | journal=Eur Respir J | year= 2020 | volume= 55 | issue= 5 | pages= | pmid=32217650 | doi=10.1183/13993003.00547-2020 | pmc=7098485 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32217650 }} </ref><ref>https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184</ref><ref>https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184</ref><ref name="pmid32145829">{{cite journal| author=Ñamendys-Silva SA| title=Respiratory support for patients with COVID-19 infection. | journal=Lancet Respir Med | year= 2020 | volume= 8 | issue= 4 | pages= e18 | pmid=32145829 | doi=10.1016/S2213-2600(20)30110-7 | pmc=7129706 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32145829 }} </ref> | ||
==References== | ==References== |
Revision as of 15:49, 18 June 2020
To go to the COVID-19 project topics list, click here.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]
Overview
Complications
Acute respiratory distress syndrome
Pneumonia
Pulmonary embolism
Hypoxemia
Superinfection
Respiratory failure
Increased mortality in COPD patients
- According to a study conducted in China, having an underlying comorbidity such as chronic obstructive pulmonary disease (COPD) conferred a mortality hazard ratio of 2.681, even after adjusting for smoking status.[1][2][3][4]
References
- ↑ Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM; et al. (2020). "Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis". Eur Respir J. 55 (5). doi:10.1183/13993003.00547-2020. PMC 7098485 Check
|pmc=
value (help). PMID 32217650 Check|pmid=
value (help). - ↑ https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184
- ↑ https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184
- ↑ Ñamendys-Silva SA (2020). "Respiratory support for patients with COVID-19 infection". Lancet Respir Med. 8 (4): e18. doi:10.1016/S2213-2600(20)30110-7. PMC 7129706 Check
|pmc=
value (help). PMID 32145829 Check|pmid=
value (help).